ATE187642T1 - Verwendund von norastemizol zur behandlung der allergischen rhinitis - Google Patents

Verwendund von norastemizol zur behandlung der allergischen rhinitis

Info

Publication number
ATE187642T1
ATE187642T1 AT93921359T AT93921359T ATE187642T1 AT E187642 T1 ATE187642 T1 AT E187642T1 AT 93921359 T AT93921359 T AT 93921359T AT 93921359 T AT93921359 T AT 93921359T AT E187642 T1 ATE187642 T1 AT E187642T1
Authority
AT
Austria
Prior art keywords
treatment
allergic rhinitis
norastemizole
compound
formula
Prior art date
Application number
AT93921359T
Other languages
English (en)
Inventor
Raymond L Woosley
A K Gunnar Aberg
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of ATE187642T1 publication Critical patent/ATE187642T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
AT93921359T 1992-09-03 1993-09-03 Verwendund von norastemizol zur behandlung der allergischen rhinitis ATE187642T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94005492A 1992-09-03 1992-09-03
PCT/US1993/008349 WO1994007495A1 (en) 1992-09-03 1993-09-03 Use of norastemizole for the treatment of allergic disorders

Publications (1)

Publication Number Publication Date
ATE187642T1 true ATE187642T1 (de) 2000-01-15

Family

ID=25474141

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99200247T ATE257704T1 (de) 1992-09-03 1993-09-03 Pharmazeutische zusammensetzungen enthaltend norastemizol.
AT93921359T ATE187642T1 (de) 1992-09-03 1993-09-03 Verwendund von norastemizol zur behandlung der allergischen rhinitis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99200247T ATE257704T1 (de) 1992-09-03 1993-09-03 Pharmazeutische zusammensetzungen enthaltend norastemizol.

Country Status (13)

Country Link
US (5) US6130233A (de)
EP (3) EP0658110B1 (de)
JP (3) JPH08501083A (de)
AT (2) ATE257704T1 (de)
AU (1) AU687746B2 (de)
CA (1) CA2143610C (de)
DE (3) DE69327328T2 (de)
DK (2) DK0920865T3 (de)
ES (2) ES2210957T3 (de)
GB (1) GB2285219B (de)
GR (1) GR3032541T3 (de)
PT (2) PT658110E (de)
WO (1) WO1994007495A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) * 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
CA2284705A1 (en) * 1997-03-26 1998-10-01 Sepracor Inc. Chemically and thermally stable norastemizole formulations
US6248308B1 (en) * 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
WO2003000264A1 (en) * 2001-06-20 2003-01-03 Schering Corporation Antihistamines for the treatment of nasal congestion and nasal obstruction
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
EP2120945A1 (de) * 2007-02-28 2009-11-25 Collegium Pharmaceutical, Inc. Antihistamin-kombination
US20080306116A1 (en) * 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
WO2009089134A1 (en) 2008-01-04 2009-07-16 Src, Inc. Methods for measuring a patint response upon administration of a drug and compositions thereof
EP2106784B1 (de) * 2008-04-03 2015-04-22 Rohm and Haas Company Haarstylingzusammensetzung
CA3124579C (en) 2020-07-15 2026-03-31 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
JP2023534810A (ja) 2020-07-15 2023-08-14 シャバー リサーチ アソシエイツ エルエルシー 急性痛の処置並びに胸やけの重症度及び／又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219559A (en) * 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
EP0144101B1 (de) * 1983-11-30 1991-02-06 Janssen Pharmaceutica N.V. Bizyklisches Heterozyklyl aufveisende N-(bizyklisches Heterozyklyl-4-piperidinamine
CA1327579C (en) * 1986-02-03 1994-03-08 Frans Eduard Janssens Anti-histaminic compositions containing n-heterocyclyl-4-piperidinamines
US4835161A (en) * 1986-02-03 1989-05-30 Janssen Pharmaceutica N.V. Anti-histaminic compositions containing n-heterocyclyl-4-piperidinamines
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
NZ520907A (en) 1997-12-23 2004-05-28 Schering Corp Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine

Also Published As

Publication number Publication date
JP2002308772A (ja) 2002-10-23
US6187795B1 (en) 2001-02-13
US6268382B1 (en) 2001-07-31
EP0658110B1 (de) 1999-12-15
DE4394931T1 (de) 1995-07-20
JP2002255817A (ja) 2002-09-11
DE69327328D1 (de) 2000-01-20
ATE257704T1 (de) 2004-01-15
US6130233A (en) 2000-10-10
PT920865E (pt) 2004-06-30
JPH08501083A (ja) 1996-02-06
CA2143610C (en) 2004-08-24
WO1994007495A1 (en) 1994-04-14
EP0920865A1 (de) 1999-06-09
PT658110E (pt) 2000-06-30
DE69333387T2 (de) 2004-12-09
ES2210957T3 (es) 2004-07-01
DK0658110T3 (da) 2000-04-17
US6124320A (en) 2000-09-26
GB2285219B (en) 1996-09-11
DE69327328T2 (de) 2000-06-21
AU4848093A (en) 1994-04-26
CA2143610A1 (en) 1994-04-14
GB9504329D0 (en) 1995-04-26
EP0920865B1 (de) 2004-01-14
GR3032541T3 (en) 2000-05-31
EP1262183A1 (de) 2002-12-04
US6187794B1 (en) 2001-02-13
ES2139673T3 (es) 2000-02-16
DE69333387D1 (de) 2004-02-19
AU687746B2 (en) 1998-03-05
GB2285219A (en) 1995-07-05
EP0658110A1 (de) 1995-06-21
DK0920865T3 (da) 2004-04-19

Similar Documents

Publication Publication Date Title
DE69327328D1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
ATE162399T1 (de) Terfanadin metaboliten und deren optisch reine isomere zur behandlung von allergischen krankheiten
ATE339187T1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
DE68912459D1 (de) Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten.
DE60018409D1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE3884878D1 (de) Uricosuretische Zusammensetzung.
ATE316373T1 (de) Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee